Positive new real-world data for Gilotrif in NSCLC

German family-owned pharma major Boehringer Ingelheim today announced results from a retrospective, observational real-world study assessing the impact of dose adjustments of Gilotrif (afatinib) on safety and efficacy in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC).

The study showed that dose adjustment with Gilotrif helped improve patient tolerability while maintaining treatment efficacy and reduced the frequency and intensity of drug reactions. These findings, which were consistent with clinical trials, were published online by the American Society of Clinical Oncology (ASCO) in advance of its 2018 annual conference.

“Clinical studies have already indicated that tolerability-guided dose adjustment may be possible with Gilotrif to manage known adverse drug reactions without impacting efficacy,” said study investigator Balazs Halmos, director, Thoracic/Head and Neck Oncology, Professor of Clinical Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York. “Through this study, we better understand the real-world effect of tailoring the dose of Gilotrif when needed in patients with EGFR mutation-positive lung cancer.”